Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
50.63 USD   +1.69%
11/22Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
GL
11/21Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy
AQ
11/18Apellis Says FDA Accepts Amended New Drug Application for Eye Disease Drug Candidate; Shares Higher
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference

09/12/2022 | 04:06pm EST

WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced updated timing for its fireside chat at an upcoming investor conference hosted by Bank of America.

Updated Conference Details

  • Bank of America Global Healthcare Conference: Fireside chat on Friday, September 16, 2022 at 9:55 a.m. BST / 4:55 a.m. ET.

The conference events will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. Replays of the webcasts will be available for 30 days following the event.

About Apellis 
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in complement, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. We are advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.

Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178

 


All news about APELLIS PHARMACEUTICALS, INC.
11/22Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
GL
11/21Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 20..
AQ
11/18Apellis Says FDA Accepts Amended New Drug Application for Eye Disease Drug Candidate; S..
MT
11/18Sector Update: Health Care Stocks Advance Pre-Bell Friday
MT
11/18Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 20..
GL
11/18Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 20..
CI
11/16JPMorgan Adjusts Price Target on Apellis Pharmaceuticals to $79 From $81, Maintains Ove..
MT
11/11North American Morning Briefing: Fed Hopes, China -3-
DJ
11/10Insider Sell: Apellis Pharmaceuticals
MT
11/10Jefferies Downgrades Apellis Pharmaceuticals to Hold From Buy, Adjusts Price Target to ..
MT
More news
Analyst Recommendations on APELLIS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 77,7 M - -
Net income 2022 -662 M - -
Net cash 2022 391 M - -
P/E ratio 2022 -8,05x
Yield 2022 -
Capitalization 5 593 M 5 593 M -
EV / Sales 2022 66,9x
EV / Sales 2023 25,4x
Nbr of Employees 476
Free-Float 84,6%
Chart APELLIS PHARMACEUTICALS, INC.
Duration : Period :
Apellis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APELLIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 50,63 $
Average target price 74,24 $
Spread / Average Target 46,6%
EPS Revisions
Managers and Directors
Cedric Francois President, Chief Executive Officer & Director
Timothy Eugene Sullivan Chief Financial Officer & Treasurer
Lok Chung Chan Chairman
Pascal Deschatelets Chief Scientific Officer
Federico Grossi Chief Medical Officer
Sector and Competitors